MitoSwab vs. ME Screen: Which Test Actually Measures Your Mitochondria?

Edited by Samael A. Tejada, Founder & Editor-in-Chief

The short answer: These two tests sound like competitors, but they do not measure the same thing. MitoSwab (ReligenDX) measures enzyme activity in your own cheek cells — your mitochondria, directly, though only two enzymes in one low-energy tissue. ME Screen does not measure your mitochondria at all: it takes your blood serum, drips it onto a standard laboratory cell line, and measures how those cells' mitochondria behave in your serum, then compresses the result into a proprietary score. MitoSwab is the more direct test and the only one with a published validation study against muscle biopsy, so it is the more defensible choice when mitochondrial disease is suspected — though its accuracy is modest and expert reviews are lukewarm. ME Screen is built for wellness tracking and gives a broader, more dynamic-looking report, but no peer-reviewed study validating the commercial test could be found, and its score's scale, norms, and reproducibility are unpublished. Neither test is cleared or approved by the FDA, and neither can diagnose mitochondrial disease on its own.

What does MitoSwab actually measure?

MitoSwab starts with a swab of the inside of your cheek — two swabs, one per cheek, collected at home. The lab extracts protein from your cheek cells and measures the activity of two electron transport chain enzymes, Complex I and Complex IV, plus citrate synthase, a marker of how much mitochondrial material the cells contain. Results come back as enzyme activity expressed against control ranges: essentially, how hard two of your mitochondria's key machines can run, compared with healthy reference values.

That is a real measurement of your own mitochondria — your cells, your enzymes. Its limits are built into the design. Cheek cells are a low-energy, fast-turnover tissue, not muscle, brain, or heart. The assay runs on broken-up cell extract, so it measures the maximum capacity of two isolated enzymes, not breathing, energy production, or stress response in a living cell. There is no oxygen consumption, no ATP measurement, no composite score.

Practical details: a physician must order it, and results go to that physician. The price on the lab's own requisition form is $350, cash-pay. You must stop mitochondria-related supplements — CoQ10, carnitine, alpha-lipoic acid, PQQ, NADH — at least seven days before swabbing, and the sample is temperature-sensitive: overnight shipping, and never on a Friday.

What does ME Screen actually measure?

ME Screen starts with a finger-prick: a few drops of blood on a special card that separates and dries the serum, stable at room temperature for weeks by the company's account. Anyone can buy it online for $699 — no prescription — and results arrive two to three weeks after the lab receives the sample.

Here is the part the marketing does not lead with. The lab rehydrates your dried serum and applies it to a proprietary line of living laboratory cells. It then measures those cells: how fast they consume oxygen, how much reactive oxygen species they produce under stress, how their mitochondrial networks hold together — grouped into Energy Profile, Mito ROS, Mito Network, and Energy Balance scores, and combined into a single composite the company calls the mescore.

The technology is genuinely sophisticated — live-cell respirometry and imaging under stress conditions is a richer readout than an enzyme assay. But the mitochondria being stressed, imaged, and scored belong to the cell line, not to you. What is yours is the serum: the mix of hormones, inflammatory signals, metabolites, nutrients, and medications circulating in your blood that day. The published predecessor of this method, from the research group behind the product, used human plasma applied for one hour to cultured mouse muscle cells. The idea is that your blood carries a “metabolic profile” that healthy cells will adopt. Whether that idea holds up is the central scientific question, and it is examined below.

Whose mitochondria does each test measure?

This is the question that decides the comparison.

• MitoSwab: yours. The enzymes come out of your own cheek cells, so your own mitochondrial genetics and acquired enzyme damage are, in principle, in the tube. Its weakness is where it looks (cheek, not muscle) and how (two enzymes in an extract, not a living system).
• ME Screen: not yours. By design, it cannot detect an inborn mitochondrial defect — a faulty gene, a broken Complex I — unless that defect happens to change your blood chemistry enough to alter how a healthy standard cell behaves. And the reverse problem is just as real: an infection, a hard workout, a big meal, a new medication, or a bad night's sleep can change your serum — and therefore your score — without your mitochondria changing at all.

How accurate is MitoSwab? What does its validation show?

MitoSwab has one genuine validation paper: a 2012 study in Molecular Genetics and Metabolism (Goldenthal and colleagues) comparing buccal swab results with muscle biopsy in 40 patients who were already known to have Complex I or Complex IV defects in muscle, against 106 healthy controls. The swab found the same defect in about 82.5% of cases — 20 of 26 Complex I defects, all 7 isolated Complex IV defects, and 6 of 7 combined defects. The company markets this as “84% correlation with muscle biopsy”; the paper itself says just over 82%.

Read carefully, that study both helps and limits the test:

• Everyone in the patient group was enrolled because their muscle biopsy was already abnormal, and the control group was healthy. That design can show agreement in known cases; it cannot tell you how the test performs on an undiagnosed person walking into a clinic, where the honest sensitivity and specificity are unknown.
• One in four isolated muscle Complex I defects was missed in cheek cells. A normal MitoSwab does not rule out mitochondrial disease.
• The study was run by the laboratory that developed the method — not an independent group — in a mostly pediatric cohort, using 2012-era technology.
• Repeatability is modest: repeat measurements of the same person varied by roughly 13–16% between runs. Changes smaller than that may be noise, which matters if the test is used to “monitor therapy.”
• Independent experts have cooled on it since. A 2018 review from Children's Hospital of Philadelphia concluded that buccal enzyme testing has “overall poor sensitivity and specificity” for mitochondrial disease and has not been proven to reflect enzyme problems in high-energy tissues like muscle and brain. The Mitochondrial Medicine Society's consensus statement says the method “needs further validation.”

Evidence label: Preliminary — a real but developer-run validation, with independent expert opinion notably cooler than the marketing.

How accurate is ME Screen? What does its validation show?

No peer-reviewed study validating the commercial ME Screen test could be found — no patient cohort, no published reference ranges, no published test-retest reliability for the mescore, and no comparison against muscle biopsy, genetic diagnosis, or the standard research methods that measure a patient's own blood cells. The company says the platform was screened at UC San Diego against more than 60 FDA-approved compounds known to affect mitochondria, and that it could detect their effects. That may show the assay reacts to drugs in a dish. It is not clinical validation, and the underlying data are unpublished.

What exists in print:

• A 2025 Scientific Reports pilot (n=20, POTS patients, no control group) using the predecessor plasma-transfer method: one measure of mitochondrial ATP production rose after a time-restricted-eating program; the stress measures did not change.
• A 2026 Frontiers in Sports and Active Living pilot (n=20, no control group) that used ME Screen as its measuring stick for a wearable light-therapy device — a study funded by the device's maker, whose authors concede the assay “may not fully capture tissue-specific adaptations.”
• And a direct challenge to the underlying premise: a large, pre-registered 2026 PLoS ONE study (Ryback and colleagues) applied blood serum from 67 ME/CFS patients and 53 healthy controls to healthy muscle cells across more than 1,700 mitochondrial stress tests — and found no difference at all. That study did not test ME Screen itself, and ME Screen reads more than the single measure used there. But it is the best independent evidence on whether serum transfer reveals disease in a dish, and it came back negative.

Meanwhile, ME Screen does not publish the things a buyer would need to interpret a score: the mescore's scale and cut-offs, how it is weighted, the size and makeup of the “normative database” it is benchmarked against, or how much a score normally wobbles between two tests of the same person. Without those numbers, no one — including the buyer — can say whether a mescore that moves ten points means improvement, noise, or last week's cold.

Evidence label: Absent — for the commercial test itself, published validation could not be found; only unpublished company claims and small uncontrolled pilots that use the test rather than test it.

Side by side: MitoSwab vs. ME Screen

Which test is more accurate for suspected mitochondrial disease?

MitoSwab — by default, and with real reservations. It is the only one of the two ever compared against muscle biopsy in people with mitochondrial disease, it runs inside a CLIA-certified, physician-ordered pathway, and it measures the patient's own biology. ME Screen should not be used for this question at all: its maker says it is not intended to diagnose anything, and it has never been studied in mitochondrial-disease patients — and by design it cannot see an inborn mitochondrial defect directly.

But the larger truth matters more than the head-to-head: neither test is a diagnosis. Modern mitochondrial-disease work-ups are led by genetic testing (mitochondrial DNA plus nuclear gene testing), with tissue enzyme studies in a supporting role. MitoSwab missed about one in four muscle Complex I defects even in its own favorable study, expert reviewers rate buccal testing's sensitivity and specificity as poor, and a normal result on either test rules nothing out. If mitochondrial disease is genuinely suspected, the money is better spent starting with a specialist and genetics — either test is, at most, an adjunct.

Which test is better for tracking mitochondrial health over time?

Neither has proven itself, and they fail differently.

ME Screen was designed for exactly this job: a wider, more dynamic panel, an easy dried-blood sample you can repeat, a bundled consultation, and a suggested retest rhythm of every three to four months. If its unpublished reproducibility claims are true, it is the more practical tracker. The problem is the word “if.” Tracking only means something when the test's own noise is smaller than the change you are chasing — and ME Screen publishes no noise figures, no norms, and no scale for its headline score. A mescore change currently cannot be interpreted by anyone outside the company.

MitoSwab's numbers are at least interpretable: real units, published control ranges, and known repeat variability of roughly 13–16% between runs — which also means small changes are within noise. In one small trial in children with autism, its readings moved toward normal on a mitochondrial supplement, suggesting it can register change; that has not been shown in healthy adults tracking their longevity stack.

The honest verdict for tracking: treat either result as a rough trend line, never a verdict. Standardize everything you can — time of day, fasting, exercise, illness, supplements — test at most a few times a year, and ignore small moves.

The bottom line: which one should you buy?

If a doctor suspects mitochondrial disease and wants a non-invasive biochemical data point to support a work-up, MitoSwab is the only defensible choice of the two — ordered by that doctor, interpreted alongside genetic testing, with full knowledge that it can miss real disease and that experts consider it a supporting tool at best.

If you are a healthy person curious about a mitochondrial “score” to track, understand what ME Screen's $699 buys: a sophisticated measurement of how laboratory cells behave in your blood serum, wrapped in a score whose accuracy for your mitochondria is unknown on the published record. It may prove to be a useful wellness trend tool. Today, that is a claim, not a finding.

And if the budget is the question — for the price of roughly two ME Screens, a consumer genetic test plus a specialist consultation will tell most people more about their mitochondria that is actually established. Mitochondria matter enormously to health. The tests that claim to grade them should be graded just as hard.

Where the evidence stands

• Established: MitoSwab measures your own mitochondrial enzymes. The method, analytes, and control ranges are published (Goldenthal 2012, PMID 22189081).
• Preliminary: MitoSwab agrees with muscle biopsy in known cases: ~82.5% agreement in 40 pre-selected patients vs. 106 healthy controls (marketed as 84%); developer-run, mostly pediatric, 2012.
• Contested: Buccal testing is an accurate stand-alone screen for mitochondrial disease. Independent expert reviews describe poor sensitivity and specificity and no proven reflection of high-energy tissues (Muraresku/Falk 2018, PMID 30393588; Mitochondrial Medicine Society consensus).
• Contested: Serum-transfer testing can reveal a person's mitochondrial state in laboratory cells. The method's predecessor studies are small and single-arm (Dzotsi 2025, PMID 41038948); the largest independent, pre-registered serum-transfer experiment found no patient-vs-control difference (Ryback 2026, PMID 41632778).
• Absent: ME Screen's mescore is a validated measure of your mitochondrial function. No peer-reviewed validation of the commercial test, and no published scale, norms, or reproducibility, could be found.
• Absent: Either test improves health outcomes when used to guide supplements or lifestyle changes. No published study shows score-guided decisions improving any clinical outcome for either test.